Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian D Weiss

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Nature Medicine|January 9, 2024
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Neuro-Oncology|June 3, 2022
Management of neurofibromatosis type 1-associated plexiform neurofibromasMichael J Fisher, Jaishri O Blakeley, Brian D Weiss, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Transplantation and Cellular Therapy|November 14, 2025
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter StudyZahra Hudda, Aaron Webster, Eric Anderson, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Nature Medicine|January 9, 2024
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Neuro-Oncology|June 3, 2022
Management of neurofibromatosis type 1-associated plexiform neurofibromasMichael J Fisher, Jaishri O Blakeley, Brian D Weiss, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Transplantation and Cellular Therapy|November 14, 2025
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter StudyZahra Hudda, Aaron Webster, Eric Anderson, et al.
Pageof 4